Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-01

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ntra-abdominal candidiasis is a serious infection common in critically ill patients, often leading to high mortality if not treated quickly. Standard antifungal treatments may be less effective due to growing resistance and poor drug penetration into the abdominal cavity. In critically ill patients, drug levels can vary widely due to factors like surgery, inflammation, fluid resuscitation, or extracorporeal support, increasing the risk of underdosing. Rezafungin is a new antifungal agent with a long half-life and broad activity against Candida species, offering potential advantages in this setting. However, there is currently no data on its concentration or effectiveness in the peritoneal fluid of patients with intra-abdominal sepsis. Its long half-life, coupled with repeated pharmacokinetic variations in critical care settings and the risk of insufficient concentrations, may hinder its use in this population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis

NCT06985758

Candidal Peritonitis

NOT_YET_RECRUITING PHASE4

Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit

NCT02510053

Invasive Fungal Infection

UNKNOWN NA

Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation

NCT03140748

Peritonitis Infectious Candida Infection

COMPLETED NA

Diagnostic Performance of the CandID PLUS PCR for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients

NCT07005258

Intra-Abdominal Infection Candida Peritonitis Infectious +2 more

COMPLETED

Pharmacokinetics of Micafungin in Patients of Intensive Care Units

NCT02164890

Invasive Candidiasis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intra-Abdominal Infection Candida Abdominal Surgery Patients Critically Ill Intensive Care Unit Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adult critically ill patients with suspected or confirmed intra-abdominal candidiasis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18 years
* with a suspected intra-abdominal candidiasis requiring abdominal surgery
* and receiving the administration of rezafungin as first-line empirical antifungal treatment just before the abdominal surgery
* and having abdominal drain for at least 2 days after the surgery